Taienkang announced that Jiangsu Bochuangyuan Biomedical Technology Co., Ltd., a holding subsidiary of the company, had previously completed the enrollment of all subjects in CKBA cream for rosacea phase IIb in May 2026 and initiated phase IIb clinical trials ahead of schedule; recently, the Phase IIb clinical trial completed the enrollment of the first test subjects, and the recruitment and screening of other subjects is progressing at an accelerated pace.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.